Cosentyx

Sep 14, 2026

Summary Novartis faced an unusually difficult period in late August–September 2026, with two Phase 3 programs (pelacarsen and del-desiran) failing their primary endpoints and eight rap-cel autoimmune trials paused following three patient deaths. The back-to-back setbacks triggered a sharp market response, wi...

Sep 13, 2024

Currently, leading hidradenitis suppurativa drugs on the market include UCB Biopharma’s BIMZELX (bimekizumab), Novartis’ COSENTYX (secukinumab), and AbbVie/Eisai’s HUMIRA (adalimumab). HUMIRA dominated the market until 2023, despite its US composition-of-matter patent expiring in December 2016. AbbVie maintained a ...

Sep 06, 2024

Hidradenitis suppurativa is a chronic inflammatory skin disease that affects the hair follicles and apocrine sweat glands. Hidradenitis suppurativa affects approximately 1% of the population, with women being more commonly affected than men. It often begins after puberty, usually in the 20s or 30s. In 2023, the ...

Nov 24, 2023

While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB’s bimekizumab, recently approved as Bi...

Oct 03, 2016

Plaque psoriasis is a chronic autoimmune condition, with a buildup of dead cells as scales giving the affected area of skin a raised and red patchy look. About 2% of population in the US suffers from this disease. A new drug, Taltz (Ixekizumab), has been approved by FDA in March 2016 for its treatment. Taltz (ixekiz...